Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Avera Pharmaceutical

Overview

Investments

Unlock datapoints

Portfolio analytics

Team

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Need help with fundraising?

We offer an assisted fundraising option for startups

Learn more
Total investments 1
Portfolio companies 1
Rounds per year 0.05
Lead investments 0
Exits 1
Key employees Soon

Areas of investment

  • Information Technology
  • Software
  • Mobile Apps
  • Enterprise Software
Summary

Avera Pharmaceutical is the famous Corporate Investor, which was founded in 2002. The venture was found in North America in United States. The main office of represented Corporate Investor is situated in the Carlsbad.

The higher amount of exits for fund were in 2019. The fund is constantly included in less than 2 investment rounds annually. The top activity for fund was in 2015.

Moreover, a startup needs to be at the age of 16-20 years to get the investment from the fund. Among the most successful fund investment fields, there are Information Technology, Software. For fund there is no match between the location of its establishment and the land of its numerous investments - Finland. Among the various public portfolio startups of the fund, we may underline Bitbar

The typical case for the fund is to invest in rounds with 7 participants. Despite the Avera Pharmaceutical, startups are often financed by Finnvera Venture Capital, Qualcomm Ventures, Draper Esprit. The meaningful sponsors for the fund in investment in the same round are Qualcomm Ventures, Nordic Venture Partners (Sweden), Inventure.

Read more

Look at other 50 related and similar funds Collapse list
Fund NameLocation
AUFI -
Cazador Acquisition Corporation Ltd Bulgaria, Grad Sofiya, Sofia
Celeres Investments China, Hong Kong, Hong Kong Island
Circularity Capital City of Edinburgh, Scotland, United Kingdom
CyberLab Ventures -
Dartmouth-Hitchcock Medical Center Lebanon, New Hampshire, United States
Escondido Ventures San Antonio, Texas, United States
Huashu Chuanmei China, Hangzhou, Zhejiang
Ideate Investments China, Shanghai
Les Crudettes -
Lion Brothers Company Maryland, Owings Mills, United States
Muzhitong Technology China, Hubei, Wuhan
Nihon Zaitaku Group Japan, Tokyo
Oriza Ventures California, Santa Clara, United States
Prisma Capital Brazil, Itaim, Minas Gerais
Splunk California, San Francisco, United States
Sycamore Ventures New Jersey, Princeton, United States
The Sapling Fund Columbus, Ohio, United States
Threadless Chicago, Illinois, United States

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Bitbar

Enterprise Software
Information Technology
Mobile Apps
Software
21 May 2015 Helsinki, Uusimaa, Finland

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Avera Pharmaceutical?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Total investments 1
Rounds per year 0.05
Peak activity year 2015
Lead investments 0
Exits 1
Group Appearance index 1.00

Latest deals

CompanyIndustryRound SizeDateInvestorsLocation

Bitbar

Enterprise Software
Information Technology
Mobile Apps
Software
21 May 2015 Helsinki, Uusimaa, Finland
Crunchbase icon

Content report

The following text will be sent to our editors: